Evolus signed term loans of up to $250,000,000 in three tranches, with $150,000,000 advanced at the effective date. The loans carry 3-month SOFR plus 5.0%, with a 3.50% floor, and mature five years after the first tranche. Early repayment carries an exit payment of 2% of principal prepaid.
Latest Evolus news
We have not published a story on Evolus yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $45.2 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Evolus
What is the ticker symbol of Evolus?
Evolus, Inc. trades under the ticker EOLS on NASDAQ.
Where is Evolus listed?
Evolus, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:EVL; LSX:A2JDYX.
What is the SEC CIK of Evolus?
The SEC Central Index Key (CIK) for Evolus, Inc. is 1570562. Its filings are on SEC EDGAR.
How many shares does Evolus have outstanding?
66,050,440 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05.
Which country or territory is Evolus listed under?
Our directory records Evolus, Inc. under United States.
What does Evolus do?
Our directory classifies Evolus, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Evolus?
The ISIN recorded for Evolus, Inc. is US30052C1071.
Does aibio.space cover Evolus?
aibio.space lists Evolus, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Evolus incorporated?
SEC records list its state or country of incorporation as DE.
What was Evolus's revenue last year?
$297.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Evolus profitable?
Evolus, Inc. reported a net loss of $51.6 million for the fiscal year ended Dec 31, 2025, and used $42.3 million of cash in operations, per its annual report to the SEC.
How much cash does Evolus have?
$45.2 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest Evolus (EOLS) stock news?
Our latest story on Evolus, dated May 5, 2025: "Evolus signs amended loan agreement with $150,000,000 first tranche to refinance debt". Evolus signed term loans of up to $250,000,000 in three tranches, with $150,000,000 advanced at the effective date. The loans carry 3-month SOFR plus 5.0%, with a 3.50% floor, and mature five years after the first tranche. Early repayment carries an exit payment of 2% of principal prepaid. Source.
Does Evolus have debt, a term loan or convertible notes?
Our latest debt story, dated May 5, 2025: "Evolus signs amended loan agreement with $150,000,000 first tranche to refinance debt". Evolus signed term loans of up to $250,000,000 in three tranches, with $150,000,000 advanced at the effective date. The loans carry 3-month SOFR plus 5.0%, with a 3.50% floor, and mature five years after the first tranche. Early repayment carries an exit payment of 2% of principal prepaid. Source.
What is Evolus's market cap?
We do not publish live share prices. In its annual report, Evolus, Inc. put the market value of shares held by non-affiliates (public float) at $560.4 million as of Jun 30, 2025.
Investor discussion: Evolus
Members talk about Evolus (EOLS). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Evolus, newest first. Each line links the filing it comes from.
Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:EOLS on TradingView.
SEC filings and registration
SEC name
Evolus, Inc.
CIK
1570562
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
EOLS (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Accelerated filer
Business address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH, CA, 92660
Phone
(949) 284-4555
Shares outstanding
66,050,440 as of 2026-07-31 (10-Q filed 2026-08-05)
Former names
Evolus, Inc.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Evolus, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker EOLS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio